Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1994 1
2001 1
2002 1
2003 1
2004 1
2005 1
2007 2
2008 1
2011 1
2012 1
2015 2
2016 1
2017 1
2018 1
2021 1
2022 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
How I diagnose and treat chronic myelomonocytic leukemia.
Patnaik MM. Patnaik MM. Haematologica. 2022 Jul 1;107(7):1503-1517. doi: 10.3324/haematol.2021.279500. Haematologica. 2022. PMID: 35236051 Free PMC article.
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/myeloproliferative overlap neoplasm characterized by sustained peripheral blood monocytosis and an inherent risk for transformation to acute myeloid leukemia (15-30% over 3-5 y …
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/myeloproliferative overlap neoplasm characterized …
Juvenile myelomonocytic leukemia.
Niemeyer CM, Kratz C. Niemeyer CM, et al. Curr Treat Options Oncol. 2003 Jun;4(3):203-10. doi: 10.1007/s11864-003-0021-z. Curr Treat Options Oncol. 2003. PMID: 12718797 Review.
Juvenile myelomonocytic leukemia is an aggressive neoplasia of early childhood. Only allogeneic stem cell transplantation (SCT) offers a long-term cure. ...Hypersensitivity for granulocyte-macrophage colony-stimulating factor and pathologic activation of the Ras/MAP …
Juvenile myelomonocytic leukemia is an aggressive neoplasia of early childhood. Only allogeneic stem cell transplantation (SCT …
Chronic myelomonocytic leukemia.
Bennett JM. Bennett JM. Curr Treat Options Oncol. 2002 Jun;3(3):221-3. doi: 10.1007/s11864-002-0011-6. Curr Treat Options Oncol. 2002. PMID: 12057067 Review.
Chronic myelomonocytic leukemia (CMML) has dysplastic and proliferative features. The median age of patients with CMML is 70 years; the median survival is approximately 2 years. ...If a donor cannot be identified, then combination acute myeloid leukemia …
Chronic myelomonocytic leukemia (CMML) has dysplastic and proliferative features. The median age of patients with CMML …
Eosinophilia in Hematologic Disorders.
Falchi L, Verstovsek S. Falchi L, et al. Immunol Allergy Clin North Am. 2015 Aug;35(3):439-52. doi: 10.1016/j.iac.2015.04.004. Immunol Allergy Clin North Am. 2015. PMID: 26209894 Free PMC article. Review.
Eosinophilia in the peripheral blood can be the manifestation various medical conditions, including benign or malignant disorders. There are 3 main types of eosinophilia-associated myeloid neoplasms (MN-eos): myeloid and lymphoid neoplasms, chronic eosinophilic l …
Eosinophilia in the peripheral blood can be the manifestation various medical conditions, including benign or malignant disorders. There are …
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M. Jetani H, et al. Blood. 2021 Nov 11;138(19):1830-1842. doi: 10.1182/blood.2020009192. Blood. 2021. PMID: 34289026 Free PMC article.
In addition, we confirmed Siglec-6 expression on transformed B cells in chronic lymphocytic leukemia (CLL), and specific anti-CLL reactivity of Siglec-6 CAR T cells in vitro. ...These data suggest that Siglec-6 CAR T-cell therapy may be used to effectively treat …
In addition, we confirmed Siglec-6 expression on transformed B cells in chronic lymphocytic leukemia (CLL), and specific anti- …
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Adès L, et al. Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334. Blood Adv. 2022. PMID: 35728048 Free PMC article. Clinical Trial.
PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia …
PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients …
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A. Santini V, et al. Leukemia. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13. Leukemia. 2018. PMID: 28607470 Free PMC article. Clinical Trial.
Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. ...After a median follow-up of 51.5 months (range: 44.4-57.2), median overall survival was 17 months, with r …
Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS …
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.
Watts J, Minden MD, Bachiashvili K, Brunner AM, Abedin S, Crossman T, Zajac M, Moroz V, Egger JL, Tarkar A, Kremer BE, Barbash O, Borthakur G. Watts J, et al. Ther Adv Hematol. 2024 Sep 14;15:20406207241275376. doi: 10.1177/20406207241275376. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39290981 Free PMC article.
BACKGROUND: GSK3326595 is a potent, selective, reversible protein arginine methyltransferase 5 (PRMT5) inhibitor under investigation for treatment of myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AM …
BACKGROUND: GSK3326595 is a potent, selective, reversible protein arginine methyltransferase 5 (PRMT5) inhibitor under investigation for tre …
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.
Gu Y, Estcourt LJ, Doree C, Hopewell S, Vyas P. Gu Y, et al. Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD011577. doi: 10.1002/14651858.CD011577.pub2. Cochrane Database Syst Rev. 2015. PMID: 26436602 Free PMC article.
MDS is predominantly a disease of the elderly, with many elderly people managed conservatively with regular allogeneic red blood cell (RBC) transfusions to treat their anaemia. However, RBC transfusions are not without risk. Despite regular transfusions playing a central r …
MDS is predominantly a disease of the elderly, with many elderly people managed conservatively with regular allogeneic red blood cell (RBC) …
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Rodriguez V, et al. Pediatr Blood Cancer. 2007 Aug;49(2):212-5. doi: 10.1002/pbc.20648. Pediatr Blood Cancer. 2007. PMID: 16261610 Review.
Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. ...In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on d …
Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after …
18 results